Semax is an analogue of ACTH(4-7)Pro-Gly-Pro studied for BDNF upregulation, neuroprotective effects, dopaminergic and serotonergic pathway modulation, and cognitive function research.
| Molecular Weight | 813.94 g/mol |
| Purity | >98% |
| Form | Lyophilized powder |
| Storage | -20°C |
Science-backed research overview for this compound
Semax is a synthetic heptapeptide based on a fragment of Adrenocorticotropic Hormone (ACTH). It was originally developed in Russia for the treatment of stroke and brain injury, and it is known for its potent neuroprotective and nootropic properties.
Semax works by rapidly increasing the expression of Brain-Derived Neurotrophic Factor (BDNF) and Nerve Growth Factor (NGF) in the brain. It also modulates the dopaminergic and serotonergic systems. Unlike many stimulants, Semax enhances cognitive function through biological repair and protection rather than just forcing neurotransmitter release.
Research into Semax focuses on its role in recovering from ischemic stroke, preventing cognitive decline, and treating ADHD. It has shown the ability to protect neurons from hypoxia (lack of oxygen) and improve memory, focus, and mental clarity in research models under stress.